Evidence map›Paper›PMID 40473906›Full record

ReviewAdvances in therapy2025

GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review.

Dimitrios Pantazopoulos, Evanthia Gouveri, Massimo Papi, Dimitrios Papazoglou, Nikolaos Papanas

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dimitrios PantazopoulosDiabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, 68100, Alexandroupolis, Greece.
Evanthia GouveriDiabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, 68100, Alexandroupolis, Greece.
Massimo PapiNational Institute for Health, Migration and Poverty (NIHMP), ADOI National Study Group Vulnology and Vascular Dermatology, Rome, Italy.
Dimitrios PapazoglouDiabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, 68100, Alexandroupolis, Greece.
Nikolaos PapanasDiabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, 68100, Alexandroupolis, Greece. papanasnikos@yahoo.gr.ORCID http://orcid.org/0000-0002-7320-785X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is) are well-established agents for type 2 diabetes mellitus (T2DM) management. Ongoing research has provided data on their both beneficial and adverse effects on the skin. For instance, GLP-1RAs have exhibited therapeutic benefits in psoriasis, while DPP-4is may reduce the risk of melanoma. Moreover, both of these agents may play a pivotal role in improving wound healing. However, untoward effects, such as bullous pemphigoid, highlight the need for patient monitoring. This review summarises the beneficial and adverse effects of GLP-1RAs and DPP-4is in dermatological conditions and in systemic diseases with cutaneous manifestations.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSkin DiseasesHumansPsoriasisDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsAdverse effectsCutaneous diseaseDPP4isGLP-1RAsSkinT2DM

Identifiers

PMID40473906
PMCPMC12313732

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.